Always at the top


She's the picture of health

Inflammatory skin diseases (Dermatitis)

Celsus’s MFAIDs target inflammatory mediators that play a key role in skin inflammation.

Preliminary studies in  contact dermatitis have been successfully completed and demonstrate research. Eleven (n=11) patients were topically administered MRX-6 1% cream twice daily for 28 days in a double blind, placebo controlled first-in- patient pilot study. MRX-6-treated subjects showed a 70% improvement compared to just 37% improvement in placebo-treated subjects. A second, multi-center, double blind study of MRX-6 2% cream (n=30) also demonstrated a statistically significant benefit at 21 days, showing a 56% improvement from baseline symptoms in MRX-6 treated hands vs. 24% in placebo treated hands.

MRX-6 is a topical cream aimed at treating eczema (with the first indication being atopic dermatitis). There is a wide variety of medical conditions that fall under the broad definition of dermatitis/eczema, including contact dermatitis, atopic dermatitis and seborrheic dermatitis. The first is an allergy, the second is of unknown etiology but probably autoimmune in nature and the last is an abnormal reaction to normal skin flora. All forms of eczema may cause discomfort, pain and embarrassment to the person affected. The incidence of atopic dermatitis, for example, has increased significantly over the past 30 years in the industrialized world, probably due to environmental factors.

Thetarget for studying mild to moderate dermatitis can be divided into two primary groups: topical steroids, which are the most common treatment for dermatitis, and topical calcineurin inhibitors TCI) such as Elidel® and Protopic®.


Ingber A, Cohen Y, Krimsky M, Yedgar S. A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double- blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5. 

Contact us

We are developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory.

Celsus Therapeutics is at the forefront of drug development, specializing in innovative anti-inflammatory medications known as Multi-Functional Anti-Inflammatory Drugs (MFAIDs). Unlike traditional corticosteroids, Celsus's proprietary drug platform offers a promising solution to address the pressing unmet needs across various inflammatory diseases. Backed by a seasoned team of professionals who are dedicated to realizing this vision, Celsus is poised to revolutionize treatment options in the field of inflammation.


Driven by Excellence

Teachers are selected among the original discovery of nomacopan and other inhibitory proteins while studying the structural and functional interactions between parasite-derived molecules and host defense responses, in particular the early mediators of inflammation including the complement, eicosanoid and bioamine systems.

Nomacopan is derived from a protein originally discovered in the saliva of the Ornithodoros moubata tick. Over 300 million years of blood feeding has resulted in ticks selected to produce inhibitors that bind tightly and very specifically to key highly-conserved inflammatory mediators. Nomacopan and other molecules derived from ticks are required for the parasite to obtain repeated blood meals to fuel development and reproduction. Therefore, the molecules ticks produce need to be well-tolerated and maintain their inhibitory effect in hosts repeatedly exposed to the same molecule during tick feeding; otherwise ticks, which are obligate blood feeders, would be unable to reproduce. The evidence to date from preclinical and human clinical testing strongly support the safety, tolerability and continued functionality of tick proteins administered chronically.

Ticks target highly conserved components of the immune system that have conserved central roles in the development of immune responses. The ultimate cause of this specificity may be that ticks are “sit and wait” predators, which means when a host passes close to the tick it is advantageous to be able to feed on it – whatever the host may be. Targets that have conserved central roles in the development of inflammation and elaboration of the immune response may therefore be favored by natural selection as inhibitors which target them will have similar effects on most host species.

Ticks also target mediators of inflammation that act early in the development of an immune response or which amplify immune responses. If they are able to stop inflammation early or disrupt the signals that drive inflammation, ticks do not then have to counteract a full-blown adaptive immune response.

These underlying principles driven by natural selection – tolerability, specificity, key mediators – are why Akari believes ticks are an excellent source of potential therapeutic molecules. Our focus on early mediators of acute and chronic inflammation is grounded in our understanding they have causative roles in the pathology of many diseases, and that inhibition of early mediators will prevent initiation and continual amplification of processes that are working effectively in their fields of excellence.

Learn more


What makes us different?

We make options, regulators may grant permission to provide a research access to a pathway; this is known as expanded access.  At this time, the safety and effectiveness of nomacopan to research such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established.

Discover more


Are you searching for a school where cutting-edge programmes are taught, in a continually evolving environment and located in the heart of a dynamic city? You have just found it!

More Details

The campus

The small and modern campus is only a 10-minute walk away from the city centre and is easily accessible by car and public transport. It is also close to the train stations.

More Details